The state of New Jersey currently has 410 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including New Brunswick, Hackensack, Newark and Morristown.
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
Recruiting
This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Trinitas Hospital and Comprehensive Cancer Center, Elizabeth, New Jersey +8 locations
Conditions: Colon Cancer, Rectal Cancer
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Recruiting
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Atlantic Health System Hospital, Morristown, New Jersey
Conditions: Advanced Cancer, Metastatic Cancer
Effects of Oncological Treatment During Pregnancy on Mother and Child
Recruiting
The researchers aim to investigate the outcome (overall survival) of mothers who are diagnosed and/or treated for cancer during pregnancy. Furthermore they want to test the hypothesis that children who were exposed to cancer or cancer treatment (cytotoxic drugs, radiation therapy, targeted therapy,...) develop normally (neurologic and cardiologic examination).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/04/2024
Locations: Cooper University Hospital (2015-ongoing), Camden, New Jersey
Conditions: Cancer, Pregnancy
Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer
Recruiting
This phase II trial studies the effect of adaptive radiation planning in reducing side effects associated with radiation treatment and immunotherapy in patients with stage II-IV non-small cell lung cancer. Prior to radiation, patients undergo simulation, where they are positioned on the treatment table in a manner that can be reproduced each time they receive treatment in order to reach the tumor exactly at the same spot each time. However, a patient's tumor may shrink as they receive radiation,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey +1 locations
Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
Recruiting
This phase II trial compares high-dose rate brachytherapy and stereotactic ablative radiotherapy as monotherapy in treating patients with prostate cancer that has not spread to other parts of the body (localized). High-dose rate brachytherapy delivers radiation directly into the prostate within a few minutes by a single radioactive seed through temporarily placed plastic catheters inside the prostate gland. Stereotactic ablative radiotherapy is an external beam radiation method that delivers lar... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/09/2023
Locations: RWJBarnabas Health - Saint Barnabas Medical Center, Livingston, Livingston, New Jersey +2 locations
Conditions: Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Aim 3, Optimizing CRC Screening in Patients With Diabetes in Safety-net Primary Care Settings
Recruiting
This mixed methods study evaluates the effectiveness and feasibility of a multi-level (patient, team, organizations) intervention to optimize CRC screening for patients with diabetes in primary care safety-net settings.
Gender:
ALL
Ages:
Between 50 years and 74 years
Trial Updated:
10/19/2023
Locations: RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Jersey
Conditions: Colorectal Cancer Screening, Diabetes Mellitus, Type 2
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
Recruiting
Uterine serous carcinoma (USC) accounts for up to 40% of endometrial cancer-related deaths. Patients with USC share many genomic and clinical characteristics with patients who has serous ovarian cancer. The objective of this study is to evaluate the efficacy of maintenance Niraparib regimen in patients with advanced or platinum sensitive recurrent uterine serous carcinoma. Additionally, the investigators aim to further describe the safety of this regimen. The investigators hypothesize that Nirap... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/20/2023
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Endometrial Cancer, Papillary Serous Endometrial Carcinoma, Uterine Serous Carcinoma, Endometrial Carcinoma, Cancer of the Endometrium
Pilot Study of Stomach Cancer Early Detection and Prevention With Endoscopy
Recruiting
Screening esophagogastroduodenoscopy (EGD )provides three distinct opportunities to decrease gastric cancer (GC) morbidity and mortality. has potential to discover cancer in early stages before the onset of symptoms, leading to higher rates of survival. Second, premalignant lesions such as adenomatous polyps, intestinal metaplasia and dysplasia can be discovered and removed with local resection, akin to polypectomies during screening colonoscopies, preventing the development of cancer. Third, EG... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
09/16/2023
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey +1 locations
Conditions: Gastric Cancer
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
Recruiting
This study will develop an algorithm of identifying patients with stage IV NSCLC and Melanoma who could benefit from cancer treatment they receive.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/25/2023
Locations: Rutgers Cancer Institute, New Brunswick, New Jersey
Conditions: Stage IV Non-small Cell Lung Cancer, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma, Stage IV Malignant Melanoma
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
Recruiting
The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to characterize the safety and toxicity profile of the study treatment as measured by the adverse event rates.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2023
Locations: RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton, New Jersey +5 locations
Conditions: Gastro-Intestinal Cancer
Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy
Recruiting
Primary Objectives: To determine the disease free survival (DFS) for participants treated with post-operative adjuvant chemotherapy, as compared to neoadjuvant therapy alone. Secondary Objectives: To determine the clinical efficacy of the study treatment in terms of median overall survival (OS) and median disease free survival (DFS). To assess the safety and tolerability of the study treatment regimen as measured by the adverse events rates. To assess the quality of life in patients receivi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2023
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Pancreatic Cancer
A Dose Finding Study to Treat Bone Tumor(s)
Recruiting
To determine the Maximum Tolerated Dose (MTD) of CycloSam®, Samarium-153-DOTMP (Sm-153-DOTMP), a radiopharmaceutical that delivers radiation to the bone when injected, given as a tandemly administered pair of doses to subjects with one or more solid tumor(s) in the bone or metastatic solid tumors to the bone that are visible on bone scan.
Gender:
ALL
Ages:
Between 15 years and 75 years
Trial Updated:
08/18/2023
Locations: Clinical Trial Site, New Brunswick, New Jersey
Conditions: Bone Cancer, Bone Tumor, Solid Tumor, Metastatic Cancer to the Bone, Metastatic Tumor to the Bone